Background: Tuberculosis (TB) is a major cause of mortality affecting millions of people in third world countries. In DOTS monitoring of patients is facilitybased and treatment supporter-based; by these two ways patients' compliance to treatment is monitored. The aim of this study was to evaluate the role of treatment supporters and their impact on patients' treatment outcomes.
Data were extracted from the patients' TB treatment cards (TB01) and TB register (TB03) on a pre-designed form.
Inclusion criteria:
All smear positive TB patients registered during year 2008 in public sector district, sub-district hospitals and rural health centers in DOTS program with available treatment outcomes were included.
Exclusion criteria:
1) All smear negative pulmonary and extra-pulmonary cases other than sputum smear positive cases. 2) All private hospitals.
Data were recorded in a pre-designed form and were entered and analyzed by SPSS/PASWstats version 17 software. Descriptive statistics were applied, using frequencies and cross tabulation, and Pearson and Chisquare test (χ 2) were used to compare group differences for categorical variables. The level of significance was set at P<0.05. Treatment Support:
RESULTS

Baseline Characteristics:
The majority of patients (89.6%) were provided with treatment supporters, which were recorded on the TB01
form. In 404 (89.6%) cases for whom treatment supporters Table 2) .
In all registered patients, 237 (52.5%) treatment supporters were males, while 214 (47.5%) were females.
Among all the registered patients 203 (45%) were supported by LHW, 102 males and 101 females. In FM/CVT supporters, male and female distribution was 81 (52.3%), and 74 (47.7%), respectively (Table . 3). Table 4 shows that from all the registered patients, 324
(71.8%) belonged to the productive age group (15-54 yrs).
Most of them were provided with LHW (137, 67.5%), 34 
Treatment Outcomes:
Three hundred and eighty four (85.1%) were categorized as "treatment success", 31 (6.9%), as "transferred out", 17 (3.8%), as "expired", 16 (3.5%) as "defaulted" and 3 (0.7%) as "treatment failure". (Table 6 ).
Most patients with "treatment support" by LHW were categorized as treatment success and were distributed in the three age groups as 6 (3%), 130 (64%) and 53 (26.1%) cases, respectively. One hundred and fourteen patients had FM/CVT treatment supporters with 6 (3.8%), 93 (60%), and 15 (9.7%) cases, respectively in the three age groups.
Among patients with "no treatment support" 40 were declared as treatment success, with the majority of them (30, 63.8%) being in the productive age group, while the remaining 10 (21.3%) were in the older age group.
Interestingly it was noticed that all patients with age ≤ 14 years were provided with a treatment supporter and all were declared as treatment success. Among patients with "unfavorable" and "transferred out" outcomes, the majority belonged to the productive age group (Table 7) . 
Treatment Support:
Our study showed that the most preferred treatment supporters were lady health workers (45%), followed by family members and community volunteers (34.4%) and community health workers and health facility workers In our study we observed that the treatment supporter selection process was according to the national guidelines, but there were certain important issues that need to be addressed related to the direct observation. These include:
better distribution of the treatment supporters in the catchment area of the health facility, updating the treatment supporters' lists periodically and training different types of treatment supporters including LHW, CVT, and CHW.
The most important finding of this study was that a significantly higher number of rural patients preferred LHW as compared to the urban patients who preferred FM/CVT as their treatment supporters. This could be due to the social unacceptability of LHW to the patients or their families and availability or unavailability of the LHW in the urban settings. Another important finding of the study was the higher number (324, 72.8%) of cases in the productive age group (15-54 yrs). We also observed that the patients within the age group ≤ 14 yrs, were all provided with a treatment supporter.
Treatment Outcomes:
Several randomized controlled trials have been performed globally to evaluate the impact of treatment supporters on treatment outcomes. In our study, the overall treatment success rate was 85.1%. This seemed to be almost similar to the WHO target rate of 85%.
Considering the treatment success rate in patients with were self-administered. The outcomes were almost similar, with treatment success rates 67%, 62%, and 65%,
respectively. This study showed that none of the three strategies was superior to the others. In our study, although the treatment success rate was the same (85.1%) in patient with "treatment support" and "no treatment In our study, the treatment success rate was higher in rural than in urban patients (89.5% vs. 81.3%). This could be due to the social unacceptability to patients or their families and unavailability of LHW, or CHW/HFW in the urban settings. These findings are quite different from those of a study carried out in three districts in Burkina Faso where geographical distance was seen to be a particular challenge for rural patients due to the lack of transport (17) . The time and cost are another challenge for poor patients (18, 19) . It is observed that daily wagers prefer to seek health care after completing their daily work, by which time all the government health out-patient departments are closed.
In our study the treatment success rate was slightly higher in females than in males (86.9% vs. 83.5%). Similar findings have been documented in studies in Southern
Thailand, Pakistan and Southern Ethiopia (8, 9, 16 
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